Disruption of differentiation in human cancer: AML shows the way
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Although much is understood about the ways in which transcription factors regulate various differentiation systems, and one of the hallmarks of many human cancers is a lack of cellular differentiation, relatively few reports have linked these two processes. Recent studies of acute myeloid leukaemia (AML), however, have indicated how disruption of transcription-factor function can disrupt normal cellular differentiation and lead to cancer. This model involves lineage-specific transcription factors, which are involved in normal haematopoietic differentiation. These factors are often targeted in AML--either by direct mutation or by interference from translocation proteins. Uncovering these underlying pathways will improve the diagnosis and treatment of AML, and provide a working model for other types of human cancer, including solid tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Autoregulation may be a common feature of several transcriptional regulators to augment the relatively irreversible nature of differentiation processes in the hematopoietic system (60,61).”
From Potential Autoregulation of Transcription Factor PU.1 by an Upstream Regulatory Element (2005) · cites this paper as [60]
Citations
Cites
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864 · cited 1×
“What is the role of lineage-specific transcription factors on stem cells, and how does this relate to AML? Although most of the blast cells from patients with AML clearly show a lineage- and stage-specific differentiation block, several studies support the idea that it is a disease that also involves the stem-cell com…”
BackgroundBennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Purification and Characterization of Mouse Hematopoietic Stem Cells
Spangrude, G. J., Heimfeld, S., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2898810 · Cited by 2,824
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“This could be applied either in treating bone marrow ex vivo with differentiation agents, followed by bone-marrow transplantation for re-introduction into the patient, or by local therapies, such as instillation into the lung by bronchoscop”
MethodOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Whereas AML1 falls into the category of transcription factors that are involved in the development of haematopoietic cells from haemangioblasts (SCL is another), and disruption of AML1 results in loss of all definitive haematopoiesi”
Background
Research works printed but not linked: 2
- Zhang, P. et al. C/EBPα deficiency blocks granulocytic differentiation at the common myeloid progenitor stage in both adult and fetal liver myelopoiesis. Blood 98, 792a (2001).
- Duprez, E. A., Koch, H. & Tenen, D. G. C/EBPβ is an important target of PML–RARA during ATRA induced differentiation of APL cells. Blood 98, 833a (2001).
Cited by
Items 101–200 of 620
Carbone, R., Botrugno, O. A., Ronzoni, S., Insinga, A., Croce, L. D., Pelicci, P. G., & Minucci, S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1288-1296.2006 · Cited by 124
“Leukemias are characterized by an arrest at various stages of hematopoietic differentiation, following the engagement in an aberrant transcriptional program that makes leukemic blasts refractory to normal differentiating stimuli (27, 29).”
BackgroundSamaniego, R., Palacios, B. S., Domínguez‐Soto, Á., Vidal, C., Salas, A., Matsuyama, T., Sánchez‐Torres, C., de la Torre, I., Miranda‐Carús, M., Sánchez‐Mateos, P., et al. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.0613345 · Cited by 112
“C/EBP and runt-related transcription factor 1 [4, 5].”
Transcriptional dysregulation during myeloid transformation in AML
Pabst, T., & Mueller, B. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210765 · Cited by 120
“Disruption of normal differentiation represents another hallmark of AML since leukemic blasts typically display a block in their normal differentiation process at a particular stage (Tenen, 2003).”
BackgroundHistone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer
Botrugno, O. A., Santoro, F., & Minucci, S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.027 · Cited by 115
Kopantzev, E. P., MONASTYRSKAYA, G. S., Vinogradova, T. V., Zinovyeva, M. V., Костина, М. Б., Filyukova, O. B., Tonevitsky, A., Sukhikh, G. T., & Sverdlov, E. D. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.02.011 · Cited by 114
PU.1 and pRB Interact and Cooperate To Repress GATA-1 and Block Erythroid Differentiation
Rekhtman, N., Choe, K. S., Matushansky, I., Murray, S., Stopka, T., & Skoultchi, A. I. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7460-7474.2003 · Cited by 102
“However, inappropriate or untimely transcriptional repression in immature cells is also thought to be the basis for the block to differentiation present in several types of hematologic malignancies (32, 34, 58).”
BackgroundA developmental constraint model of cancer cell states and tumor heterogeneity
Patel, A. S., & Yanai, I. (2024) · Cell · doi:10.1016/j.cell.2024.04.032 · Cited by 105
Dou, X., Xiao, Y., Shen, C., Wang, K., Wu, T., Liu, C., Li, Y., Yu, X., Liu, J., Dai, Q., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01213-w · Cited by 90
Effect of transcription-factor concentrations on leukemic stem cells
Rosenbauer, F., Koschmieder, S., Steidl, U., & Tenen, D. G. (2005) · Blood · doi:10.1182/blood-2005-02-0717 · Cited by 98
Self-citationD'Alo', F., Johansen, L. M., Nelson, E. A., Radomska, H. S., Evans, E. K., Zhang, P., Nerlov, C., & Tenen, D. G. (2003) · Blood · doi:10.1182/blood-2003-02-0479 · Cited by 98
Self-citationChang, J. S., Santhanam, R., Trotta, R., Neviani, P., Eiring, A. M., Briercheck, E., Ronchetti, M., Roy, D. C., Calabretta, B., Caligiuri, M. A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078303 · Cited by 98
Helbling, D. C., Mueller, B. U., Timchenko, N. A., Schardt, J., Eyer, M., Betts, D. R., Jotterand, M., Meyer‐Monard, S., Fey, M. F., & Pabst, T. (2005) · Blood · doi:10.1182/blood-2004-11-4392 · Cited by 104
C/EBPα and the pathophysiology of acute myeloid leukemia
Mueller, B. U., & Pabst, T. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000190110.08156.96 · Cited by 112
Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia
Metcalf, D., Dakic, A., Mifsud, S., Di Rago, L., Wu, L., & Nutt, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510616103 · Cited by 95
Suh, H. C., Gooya, J., Renn, K., Friedman, A. D., Johnson, P. F., & Keller, J. R. (2006) · Blood · doi:10.1182/blood-2005-06-2216 · Cited by 95
The cell of origin and the leukemia stem cell in acute myeloid leukemia
Chopra, M., & Bohlander, S. K. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22805 · Cited by 115
Ottmann, C., Weyand, M., Sassa, T., Inoue, T., Kato, N., Wittinghofer, A., & Oecking, C. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.005 · Cited by 94
Nanri, T., Matsuno, N., Kawakita, T., Suzushima, H., Kawano, F., Mitsuya, H., & Asou, N. (2005) · Leukemia · doi:10.1038/sj.leu.2403803 · Cited by 94
Lepourcelet, M., Tou, L., Cai, L., Sawada, J.-I., Lazar, A. J., Glickman, J. N., Williamson, J. A., Everett, A. D., Redston, M. S., Fox, E. A., et al. (2004) · Development · doi:10.1242/dev.01579 · Cited by 99
“By contrast, in some leukemias and lymphomas, where relationships between tumor cells and steps in normal development or cell differentiation are defined precisely, the resulting insights guide both understanding and treatment of the disease (Tenen, 2003).”
Hughes, J. M., Legnini, I., Salvatori, B., Masciarelli, S., Marchioni, M., Fazi, F., Morlando, M., Bozzoni, I., & Fatica, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4069 · Cited by 96
“Blocks in genetic programs required for terminal myeloid differentiation and aberrant proliferation characterize acute myeloid leukemia (AML) (reviewed in [1]).”
Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia
Fazi, F., Zardo, G., Gelmetti, V., Travaglini, L., Ciolfi, A., Di Croce, L., Rosa, A., Bozzoni, I., Grignani, F., Lo-Coco, F., et al. (2007) · Blood · doi:10.1182/blood-2006-09-045781 · Cited by 88
Knockdown of PU.1 AS lncRNA inhibits adipogenesis through enhancing PU.1 mRNA translation
Pang, W.-J., Lin, L., Xiong, Y., Wei, N., Wang, Y., Shen, Q. W., & Yang, G.-S. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24595 · Cited by 103
Helbling, D., Mueller, B. U., Timchenko, N. A., Hagemeijer, A., Jotterand, M., Meyer‐Monard, S., Lister, A. T., Rowley, J. D., Huegli, B., Fey, M. F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404731101 · Cited by 100
Causes of childhood leukaemia and lymphoma
Lightfoot, T. J., & Roman, E. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.12.032 · Cited by 105
The molecular pathogenesis of acute myeloid leukemia
Steffen, B., Müller‐Tidow, C., Schwäble, J., Berdel, W. E., & Serve, H. L. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.10.012 · Cited by 111
Zhou, J., Quah, J. Y., Ng, Y., Chooi, J.-Y., Toh, S. H. M., Lin, B., Tan, T. Z., Hosoi, H., Osato, M., Seet, Q., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.230482 · Cited by 84
“The one exception to date is treatment targeting AML with mutated isocitrate dehydrogenase (IDH) 1 or 2.(8,9) Enasidenib, a selective, non-competitive inhibitor of IDH2, induces differentiation of AML cells through reducing the oncometabolite 2hydroxyglutarate in mutated IDH2.”
BackgroundChan, W. Y. I., Follows, G. A., Lacaud, G., Pimanda, J. E., Landry, J.-R., Kinston, S., Knezevic, K., Piltz, S., Donaldson, I. J., Gambardella, L., et al. (2007) · Blood · doi:10.1182/blood-2006-05-023226 · Cited by 79
“(1) Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 2XY, UK (2) Paterson Institute for Cancer Research, Christie Hospital, Manchester M20 4BX, UK (3) Institute of Genetics, The University of Nottingham, Nottingham NG7 2UH, UK (4) corresponding author: Departm…”
BackgroundZheng, X. W., Seshire, A., Rüster, B., Bug, G., Beißert, T., Puccetti, E., Hoelzer, D. T., Henschler, R., & Ruthardt, M. (2007) · Haematologica · doi:10.3324/haematol.10541 · Cited by 91
Sharabani, H., Izumchenko, E., Wang, Q., Kreinin, R., Steiner, M., Barvish, Z., Kafka, M., Sharoni, Y., Levy, J., Uskoković, M. R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21736 · Cited by 82
“lopoiesis, followed by repression of normal hematopoiesis by the expanding immature blasts.(1) Despite advances in our understanding”
BackgroundHuang, G., Zhao, X., Wang, L., Elf, S., Xu, H., Zhao, X., Sashida, G., Zhang, Y., Liu, Y., Lee, J., et al. (2011) · Blood · doi:10.1182/blood-2010-11-317909 · Cited by 79
Self-citationRunx genes are direct targets of Scl/Tal1 in the yolk sac and fetal liver
Landry, J.-R., Kinston, S., Knezevic, K., de Bruijn, M. F. T. R., Wilson, N., Nottingham, W. T., Peitz, M., Edenhofer, F., Pimanda, J. E., Ottersbach, K., et al. (2008) · Blood · doi:10.1182/blood-2007-07-098830 · Cited by 80
N6-Methyladenosine (m6A): A Promising New Molecular Target in Acute Myeloid Leukemia
Ianniello, Z., Paiardini, A., & Fatica, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00251 · Cited by 85
“In particular, AML is characterized by an accumulation of immature cells which fail to respond to normal regulators of differentiation within the bone marrow (52).”
BackgroundClinically useful prognostic factors in acute myeloid leukemia
Ferrara, F., Palmieri, S., & Leoni, F. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.09.008 · Cited by 78
Bergmann, O. J., Johansen, J. S., Klausen, T. W., Mylin, A. K., Kristensen, J. S., Kjeldsen, E., & Johnsen, H. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1317 · Cited by 78
Salvatori, B., Iosue, I., Mangiavacchi, A., Loddo, G., Padula, F., Chiaretti, S., Peragine, N., Bozzoni, I., Fazi, F., & Fatica, A. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.151 · Cited by 80
“Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy in which immature progenitor cells accumulate in the bone marrow (BM) and eventually in blood and organs interfering with the production of normal blood cells.(1) AML is characterized by genetic and epigenetic alterations in progenitor cells that…”
BackgroundSugino, N., Kawahara, M., Tatsumi, G., Kanai, A., Matsui, H., Yamamoto, R., Nagai, Y., Fujii, S., Shimazu, Y., Hishizawa, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.59 · Cited by 85
Guidez, F., Parks, S., Wong, H., Jovanovic, J. V., Mays, A. N., Gilkes, A., Mills, K., Guillemin, M.-C., Hobbs, R. M., Pandolfi, P. P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704433104 · Cited by 79
Liu, H., Kho, A. T., Kohane, I. S., & Sun, Y. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030232 · Cited by 74
“The developmental–stem cell association for non-solid cancers such as leukemia is well established [18], but the case for solid tumors is less clear.”
Kawamata, N., Ogawa, S., Zimmermann, M., Niebuhr, B., Stocking, C., Sanada, M., Hemminki, K., Yamatomo, G., Nannya, Y., Koehler, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711039105 · Cited by 80
“It has been suggested that two distinct genetic abnormalities contribute to leukemogenesis in acute myelogenous leukemia (AML); one is mutations promoting cellular proliferation, for example FLT3 or RAS mutations, and the other is mutations blocking differentiation, for example PML-RARA or RUNX1-ETO (21, 22).”
BackgroundNotch-dependent control of myelopoiesis is regulated by fucosylation
Zhou, L., Li, L. W., Yan, Q., Petryniak, B., Man, Y., Su, C., Shim, J., Chervin, S., & Lowe, J. B. (2008) · Blood · doi:10.1182/blood-2007-11-115204 · Cited by 71
Role of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia
Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05051 · Cited by 72
“In fact, genes encoding transcription factors are frequently mutated or deregulated in patients with AML (reviewed in [ 58 ]), a disease that is characterized by a differentiation block of myeloid precursors and results in accumulation of immature myeloid cells in the bone marrow and blood (Figure 2).”
BackgroundSelf-citationHoemme, C., Zada, A. A. P., Behre, G., Wang, Y., McClelland, M., Nieselt, K., Zschunke, M., Disselhoff, C., Agrawal, S., Isken, F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079921 · Cited by 72
“Balanced translocations that lead to expression of aberrant fusion proteins are a hallmark of acute leukemias.(1) Many of these fusion proteins function as aberrant transcription factors that are an initiating event in leukemogenesis.”
BackgroundHalmos, B., Bassères, D. S. D. S., Monti, S., D‘Aló, F., Dayaram, T., Ferenczi, K., Wouters, B. J., Huettner, C. S., Golub, T. R., & Tenen, D. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4052 · Cited by 78
“In particular, it is increasingly clear that aberrant regulation of transcriptional control pathways of normal differentiation is one of the most common abnormalities in hematological malignancies, such as acute myeloid leukemia (8).”
BackgroundSelf-citationDe Marchis, M. L., Ballarino, M., Salvatori, B., Puzzolo, M. C., Bozzoni, I., & Fatica, A. (2009) · Leukemia · doi:10.1038/leu.2008.372 · Cited by 71
Schardt, J., Weber, D., Eyholzer, M., Mueller, B. U., & Pabst, T. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2870 · Cited by 77
“in their normal differentiation process at a particular stage (1).”
Bueso-Ramos, C., Rocha, F. C., Shishodia, S., Medeiros, L. J., Kantarjian, H. M., Vadhan‐Raj, S., Estrov, Z. E., Smith, T. L., Nguyen, M. H., & Aggarwal, B. B. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.08.020 · Cited by 71
The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate
Schüler, A., Schwieger, M., Engelmann, A., Weber, K., Horn, S., Müller, U., Arnold, M. A., Olson, E. N., & Stocking, C. (2008) · Blood · doi:10.1182/blood-2007-10-116343 · Cited by 70
“There are 3 main conclusions that can be made from our study: (1) Mef2c modulates monocytic differentiation at the expense of granulocytic differentiation; (2) Mef2c activity is regulated by external stimuli, such as cytokines and endotoxins, indicative of an important role in immune response; and (3) c-Jun is an impo…”
ResultEpigenetic inactivation of secreted Frizzled‐related proteins in acute myeloid leukaemia
Jost, E., Schmid, J., Wilop, S., Schubert, C., Suzuki, H., Herman, J. G., Osieka, R., & Galm, O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07242.x · Cited by 69
“The most important genetic findings in AML are chromosomal translocations involving different transcription factors and activating point mutations in multiple signal transduction pathways (Tenen, 2003).”
BackgroundTargeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα
Radomska, H. S., Alberich-Jordà, M., Will, B., Gonzalez, D., Delwel, R., & Tenen, D. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci43354 · Cited by 67
“FLT3 is normally expressed in early hematopoietic precursors and plays a role in their proliferation and differentiation (1, 2), but its aberrant activation contributes to the development of AML.”
Self-citationLin, K., Zhang, X., Feng, D.-D., Zhang, H., Zeng, C., Han, B., Zhou, A., Qu, L., Xu, L., & Chen, Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.269670 · Cited by 70
Zardo, G., Cimino, G. G., & Nervi, C. (2008) · Leukemia · doi:10.1038/leu.2008.141 · Cited by 75
Pandolfi, A., Barreyro, L., & Steidl, U. G. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0109 · Cited by 75
Vian, L., Di Carlo, M., Pelosi, E., Fazi, F., Santoro, S., Cerio, A. M., Boe, A., Rotilio, V, Billi, M., Racanicchi, S., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.145 · Cited by 61
“By binding cisacting elements within their target gene promoters, lineagespecific transcription factors (TFs) affect self-renewal and differentiation/maturation of hematopoietic stem/progenitor cells (HPCs).(1,2,4) MicroRNAs (miRNAs) affect key developmental hematopoietic programs.”
BackgroundWagner, K., Zhang, P., Rosenbauer, F., Drescher, B., Kobayashi, S., Radomska, H. S., Kutok, J. L., Gilliland, D. G., Krauter, J., & Tenen, D. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508143103 · Cited by 66
Self-citationCDK6 Inhibition: A Novel Approach in AML Management
Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 78
Braess, J., Spiekermann, K., Staib, P., Grüneisen, A., Wormann, B. J., Ludwig, W.-D., Serve, H. L., Reichle, A., Peceny, R., Oruzio, D. V., et al. (2009) · Blood · doi:10.1182/blood-2008-07-162842 · Cited by 65
“Whole group 105 (61) 38 (22) 12 (7) 17 (10) 172 (100)”
InfluentialRunx1 is essential at two stages of early murine B-cell development
Niebuhr, B., Kriebitzsch, N., Fischer, M., Behrens, K., Günther, T., Alawi, M., Bergholz, U., Müller, U., Roscher, S., Ziegler, M., et al. (2013) · Blood · doi:10.1182/blood-2013-01-480244 · Cited by 62
“Notably, each of these gene loci contained >1 Runx1-occupied site that was (1) coincident with the E2A binding site; (2) flanked by H3K4me1; and (3) coincided with a DNaseI hypersensitive site, suggestive of enhancer function.”
BackgroundAnastasov, N., Bonzheim, I., Rudelius, M., Klier, M., Dau, T., Angermeier, D., Duyster, J., Pittaluga, S., Fend, F., Raffeld, M. A., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.014050 · Cited by 74
Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway
Miranda, M. B., Xu, H., Torchia, J. A., & Johnson, D. E. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.03.016 · Cited by 62
Rangatia, J., Vangala, R. K., Singh, S. M., Peer Zada, A. A., Elsässer, A., Kohlmann, A., Haferlach, T., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206664 · Cited by 62
Self-citationHuber, R., Pietsch, D., Günther, J., Welz, B., Vogt, N., & Brand, K. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1322-4 · Cited by 71
“Pathophysiological mechanisms underlying infections, inflammation, leukemia, and hyperproliferation have been extensively reviewed elsewhere [31, 34, 41].”
BackgroundDolznig, H., Grebien, F., Deiner, E. M., Stangl, K., Kolbus, A., Habermann, B. H., Kerenyi, M. A., Kieslinger, M., Moriggl, R., Beug, H., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209308 · Cited by 69
“…driven by normal or mutated cytokine receptors and receptor tyrosine kinases (RTKs), which cooperate with transcriptional and chromatin regulators as shown in culture (Schulte et al., 2002; Carotta et al., 2004; Von Lindern et al., 2004) and human leukemia (Stirewalt and Radich, 2003; Tenen, 2003).”
BackgroundC/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia
Alberich-Jordà, M., Wouters, B., Balastik, M., Shapiro-Koss, C., Zhang, H., DiRuscio, A., Radomska, H. S., Ebralidze, A. K., Amabile, G., Ye, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65102 · Cited by 59
“CCAAT/enhancer-binding proteins (C/EBPs) are a family of basic region leucine zipper DNA–binding proteins of which 6 core members have been identified: C/EBP α , C/EBP β , C/EBP γ , C/EBP δ , C/EBP ε , and C/EBP ζ (5–8).”
Self-citationSuh, H. C., Leeanansaksiri, W., Ji, M. H., Klarmann, K. D., Renn, K., Gooya, J. M., Smith, D., McNiece, I., Lugthart, S., Valk, P. J. M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.175 · Cited by 62
Order Matters: The Order of Somatic Mutations Influences Cancer Evolution
Kent, D. G., & Green, A. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027060 · Cited by 64
“This also prompted the classification of cancer genes into categories that defined types of activities (e.g., differentiation block þ proliferation advantage ¼ cancer) (reviewed in Tenen 2003).”
BackgroundAntioxidant status and superoxide anion radical generation in acute myeloid leukemia
Er, T., Tsai, S., Wu, S., Chiang, W., Lin, H., Lin, S., Wu, S.-H., Tsai, L., & Liu, T. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.05.013 · Cited by 60
Marteijn, J. A. F., van Emst, L., Erpelinck-Verschueren, C. A. J., Nikoloski, G., Menke, A. L., de Witte, T., Löwenberg, B., Jansen, J. H., & van der Reijden, B. A. (2005) · Blood · doi:10.1182/blood-2005-04-1450 · Cited by 62
“No interaction was observed between Triad1[1-119] and a panel of Ubcs28 tested, including CDC34, UbcH5, UbcH6, UbcH7, UbcH8, UbcH9, UbcH10, and UbcH13 (not shown).”
BackgroundThe pathological role and prognostic impact of miR-181 in acute myeloid leukemia
Weng, H., Lal, K., Yang, F. F., & Chen, J. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2014.12.006 · Cited by 59
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia
Doepfner, K. T., Boller, D., & Arcaro, A. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.05.005 · Cited by 58
“These include core binding factor (CBF), retinoic acid receptor the HOX family of transcription factors (Kelly & Gilliland, 2002; Steffen et al., 2005; Tenen, 2003).”
BackgroundGiacopelli, B., Wang, M., Sher, A. C., Wu, Y.-Z., Schultz, A. R., Schmutz, M., Blachly, J. S., Eisfeld, A., Mundy-Bosse, B. L., Vosberg, S., et al. (2021) · Genome Research · doi:10.1101/gr.269233.120 · Cited by 59
“Disruption of several members of these TF families are associated with a block in AML differentiation (Tenen 2003).”
InfluentialGrigorakaki, C., Morceau, F., Chateauvieux, S., Dicato, M. A., & Diederich, M. F. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.030 · Cited by 67
“monopoiesis and lymphopoiesis on the one side, and erythropoiesis on the other side [45].”
BackgroundMatsuno, N., Osato, M., Yamashita, N., Yanagida, M., Nanri, T., Fukushima, T., Motoji, T., KUSUMOTO, S., Towatari, M., Suzuki, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403160 · Cited by 60
“Fms-like tyrosine kinase 3 (FLT3) is a member of the class III receptor tyrosine kinase subfamily, including C-FMS, C-KIT and PDGFR. FLT3 is expressed in immature hematopoietic cells and plays an important role in the proliferation of hematopoietic progenitors in combination with other growth factors.(22) The internal…”
BackgroundIn Vitro Human Haematopoietic Stem Cell Expansion and Differentiation
Bozhilov, Y. K., Hsu, I., Brown, E. J., & Wilkinson, A. C. (2023) · Cells · doi:10.3390/cells12060896 · Cited by 60
Schwieger, M., Löhler, J., Fischer, M., Herwig, U., Tenen, D. G., & Stocking, C. (2003) · Blood · doi:10.1182/blood-2003-07-2280 · Cited by 64
“Interestingly, this regulation has been shown to occur at 2 levels: (1) transcriptional regulation of monocytic or erythroid transcription factors (eg, Jun-B53 and Id-17), or (2) direct binding and impairment of such factors (eg, PU.”
BackgroundSelf-citationHong, L., Samanta, S., & Nagarajan, L. (2005) · Oncogene · doi:10.1038/sj.onc.1208167 · Cited by 56
Cancer Biomarker Discovery: The Entropic Hallmark
Berretta, R., & Moscato, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012262 · Cited by 55
“[20,21], ‘‘aneuploidy’’ and ‘‘chromosome aberrations’’ [22,23,24,25,26], ‘‘disruption of cellular junctions’’ [27], ‘‘avoidance of the immune response’’ [28], ‘‘pre-existing chronic inflammatory conditions’’ [29,30], ‘‘cancerrelated inflammation’’ [29], ‘‘disabled autophagy’’ [28], ‘‘impaired cellular senescence’’ [31…”
CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
Lin, T.-C., Hou, H.-A., Chou, W.-C., Ou, D., Yu, S., Tien, H., & Lin, L. (2010) · Leukemia · doi:10.1038/leu.2010.222 · Cited by 55
Haefliger, S., Klebig, C., Schaubitzer, K., Schardt, J., Timchenko, N. A., Mueller, B. U., & Pabst, T. (2011) · Blood · doi:10.1182/blood-2010-08-304485 · Cited by 60
C/EBPα and DEK coordinately regulate myeloid differentiation
Koleva, R., Ficarro, S. B., Radomska, H. S., Carrasco-Alfonso, M. J., Alberta, J. A., Webber, J. T., Luckey, C. J., Marcucci, G., Tenen, D. G., & Marto, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-383083 · Cited by 61
Self-citationXie, V. K., Li, Z., Yan, Y., Jia, Z., Zuo, X., Ju, Z., Wang, J., Du, J., Xie, D., Xie, K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0387 · Cited by 54
“The potential reversion of epigenetically silenced tumor suppressors has emerged as a promising strategy for cancer prevention and treatment (9, 10).”
BackgroundQuintanilla‐Martínez, L., Pittaluga, S., Miething, C., Klier, M., Rudelius, M., DAVIES-HILL, T. M., Anastasov, N., Martínez, A., Vivero, A., Duyster, J., et al. (2006) · Blood · doi:10.1182/blood-2005-10-014258 · Cited by 57
Gangenahalli, G. U., Gupta, P., Saluja, D., Verma, Y. K., Kishore, V., Chandra, R., Sharma, R. K., & Ravindranath, T. (2005) · Stem Cells and Development · doi:10.1089/scd.2005.14.140 · Cited by 53
“These protein interactions elicit either positive (c-Jun) or negative (GATA-1, C/EBP (cid:1) ) effects on PU.1 function (23).”
Roos, J., Oancea, C., Heinßmann, M., Khan, D., Held, H., Kahnt, A. S., Capelo, R., la Buscató, E., Proschak, E., Puccetti, E., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3012 · Cited by 55
“These LAFPs are generated by chromosomal translocations such as t(15;17) (PML/RARa), t(8;21) (AML-1/ETO), t(9;11)(MLL/AF9), or t(9;22) (BCR/ABL; refs.”
BackgroundHsu, J., Huang, H., Chen, S., Wong, C., & Juan, H. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep107 · Cited by 53
“involved in normal hematopoietic differentiation, also participate in the pathogenesis of leukemia [7, 8].”
BackgroundChambers, C., Čermáková, K., Chan, Y. S., Kurtz, K. J., Wohlan, K., Lewis, A. H., Wang, C., Pham, A., Dejmek, M., Šála, M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2129 · Cited by 56
“5) composed of transcription factors (TF) and other regulators, including RUNX1 (6), MEIS1 (7), LMO2, and several others (8, 9), which form an autoregulatory circuit that maintains leukemic cell identity (10).”
H2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia
Kawahara, M., Pandolfi, A., Bartholdy, B., Barreyro, L., Will, B., Roth, M. E., Okoye-Okafor, U. C., Todorova, T. I., Figueroa, M. E., Melnick, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.027 · Cited by 55
“Transcription factors are critical for the regulation of normal hematopoiesis as well as leukemogenesis (Friedman, 2007; Laiosa et al., 2006; Tenen, 2003).”
Peng, L., Zhang, Y., & Xin, H. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29336 · Cited by 52
“Acute myeloid leukemia (AML) is the most aggressive malignant disease of the hematopoietic system with the characteristic of clonal proliferation of leukemia progenitor cells, which eventually leads to dysfunction in producing normal blood cells.(1) Genetic abnormalities and epigenetic alterations, which play key role…”
BackgroundEpigenetic Inactivation of the Groucho Homologue Gene TLE1 in Hematologic Malignancies
Fraga, M. F., Berdasco, M., Ballestar, E., Ropero, S., López‐Nieva, P., Lopez‐Serra, L., Martín-Subero, J. I., Calasanz, M. J., de Silanes, I. L., Setién, F., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0085 · Cited by 52
“© 2008 American Association for Cancercancerres.aacrjournals.org Downloaded from observed that TLE1 CpG island hypermethylation was a common event in B-DLCLs (36%, 17 of 47) and AMLs (24%, 6 of 25), whereas it was much less prevalent in ALLs (2.9%, 1 of 34; Fig.”
BackgroundInfluentialTrivedi, A. K., Bararia, D., Christopeit, M., Zada, A. A. P., Singh, S. M., Kieser, A., Hiddemann, W., Behre, H. M., & Behre, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209964 · Cited by 58
Qian, J., Lin, J., Qian, W., Ma, J., Qian, S., Li, Y., Yang, J. C., Li, J., Wang, C., Chai, H., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.03.014 · Cited by 51
Koschmieder, S., D'Alò, F., Radomska, H., Schöneich, C., Chang, J. S., Konopleva, M., Kobayashi, S., Levantini, E., Suh, N., Di Ruscio, A., et al. (2007) · Blood · doi:10.1182/blood-2006-11-058941 · Cited by 50
“Likewise, in HL60 cells, expression of calreticulin, a RNA-binding protein that translationally inhibits CEBPAexpression in t(3,21)(q26; q22) AML cells,24 was not affected by treatment with CDDO (not shown).”
BackgroundSelf-citationLeukemic Stem Cells: Where do They Come From?
Passegue, E. A., & Weisman, I. L. (2005) · Stem Cell Reviews and Reports · doi:10.1385/scr:1:3:181 · Cited by 61
Gediya, L. K., Belosay, A., Khandelwal, A., Purushottamachar, P., & Njar, V. C. O. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.12.007 · Cited by 51
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression
Yong, K. J., Bassères, D. S. D. S., Welner, R. S., Zhang, W. C., Yang, H. H., Yan, B., Alberich-Jordà, M., Zhang, J., de Figueiredo‐Pontes, L. L., Battelli, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6066 · Cited by 56
“We hypothesize that the C/EBPa/BMI1 axis will be central to cancer cell biology in other malignancies as well, given the numerous reports underlining both decreased activity of C/EBPa and increased expression of BMI1 in many cancer types (4, 7, 41).”
BackgroundSelf-citationDimer-tetramer transition controls RUNX1/ETO leukemogenic activity
Wichmann, C. W., Becker, Y., Chen-Wichmann, L., Vogel, V., Vojtkova, A., Herglotz, J., Moore, S., Koch, J., Lausen, J., Mäntele, W., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248047 · Cited by 55
“The ubiquitously expressed RUNX1 is a transcription factor and belongs to the key regulators of hematopoietic cell differentiation.(2)”
BackgroundSamaniego, R., Domínguez‐Soto, Á., Ratnam, M., Matsuyama, T., Sánchez‐Mateos, P., Corbí, A. L., & Puig‐Kröger, A. (2020) · Cells · doi:10.3390/cells9061445 · Cited by 57
“1, which is essential for terminal myeloid cell differentiation [49,50] and control of expression of the M-CSF receptor [51].”
BackgroundDiscovery of a novel Nrf2 inhibitor that induces apoptosis of human acute myeloid leukemia cells
Zhang, J., Su, L., Ye, Q., Zhang, S., Kung, H., Jiang, F., Jiang, G., Miao, J., & Zhao, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13825 · Cited by 48
“The disease is due to abnormal differentiation of hematopoietic stem cells and is characterized by the accumulation of abnormal blasts in bone marrow [1].”
BackgroundShih, L.-Y., Liang, D.-C., Huang, C.-F., Jh, W., Lin, T.-L., Wang, P.-N., Dunn, P., Kuo, M.-C., & Tang, T. (2006) · Leukemia · doi:10.1038/sj.leu.2404124 · Cited by 48
Brown, A. L., Wilkinson, C. R., Waterman, S. R., Kok, C. H., Salerno, D. G., Diakiw, S. M., Reynolds, B., Scott, H. S., Tsykin, A., Glonek, G. F. V., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0206112 · Cited by 53
“Proteins in these categories can influence cell fate and the switch between proliferation and differentiation [55] and are often involved in leukemic translocations resulting in fusion proteins that have the capacity to reprogram myeloid cell behavior [1].”
BackgroundNatural HDAC‐1/8 inhibitor baicalein exerts therapeutic effect in CBF‐AML
Yu, X., Li, H., Hu, P., Qing, Y., Wang, X., Zhu, M., Wang, H., Wang, Z., Xu, J., Guo, Q., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.154 · Cited by 48
Metadata
- Authors
- Tenen, D. G.
- Affiliations
- Harvard University (US)
- Corresponding author
- Tenen, Daniel G.
- ORCID
- Tenen, Daniel G.
- Venue
- Nature Reviews Cancer
- Published
- 2003-02
- Volume
- 3
- Issue
- 2
- Pages
- 89-101
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2050249118
- Cited by
- 612
- References
- 128
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 6 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 17 · 2017: 22 · 2016: 20 · 2015: 18 · 2014: 25 · 2013: 33 · 2012: 27
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- acute myeloid leukemia, cell differentiation, transcription factors, lineage-specific transcription factors, hematopoietic differentiation, transcription factor mutations, solid tumors
- MeSH terms
- Cell Differentiation, Humans, Mutation, Neoplasms, Transcription Factors, Leukemia, Myeloid, Acute
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.